Belite Bio (NASDAQ:BLTE – Get Free Report) and Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.
Analyst Ratings
This is a summary of current recommendations and price targets for Belite Bio and Tenaya Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Belite Bio | 1 | 1 | 6 | 0 | 2.63 |
| Tenaya Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
Belite Bio presently has a consensus target price of $202.33, suggesting a potential upside of 35.63%. Tenaya Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 545.16%. Given Tenaya Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Belite Bio.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Belite Bio | N/A | N/A | -$77.61 million | ($2.30) | -64.86 |
| Tenaya Therapeutics | N/A | N/A | -$90.60 million | ($0.62) | -1.00 |
Belite Bio is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Belite Bio and Tenaya Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Belite Bio | N/A | -19.49% | -19.05% |
| Tenaya Therapeutics | N/A | -85.20% | -69.96% |
Institutional & Insider Ownership
0.5% of Belite Bio shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 48.7% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
Belite Bio has a beta of -1.46, suggesting that its share price is 246% less volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 3.22, suggesting that its share price is 222% more volatile than the S&P 500.
Summary
Tenaya Therapeutics beats Belite Bio on 8 of the 12 factors compared between the two stocks.
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
About Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
